National Centre for Immunisation Research and Surveillance, Children's Hospital at Westmead, Westmead, Australia; The University of Sydney Children's Hospital Westmead Clinical School, Westmead, Australia.
Murdoch Children's Research Institute, Melbourne, Australia; Department of Paediatrics, University of Melbourne, Melbourne, Australia; Department of General Medicine, Royal Children's Hospital, Melbourne, Australia.
Vaccine. 2021 Mar 12;39(11):1565-1571. doi: 10.1016/j.vaccine.2021.02.016. Epub 2021 Feb 19.
Seizures, whether febrile or afebrile, occurring within 14 days following vaccination can be considered as vaccine proximate seizures (VPSs). While the attributable risk and clinical severity of first febrile VPS is well known, the risk and clinical outcomes of VPS recurrence is less well defined.
We conducted a retrospective review of revaccination management and outcomes in children who experienced a VPS as their first seizure seen in Australian Specialist Immunisation Clinics between 2013 and 2017. Vaccination outcomes were compared between children who had a VPS as their only seizure (VPS only) and children who had further non-vaccine proximate seizures following their initial VPS (VPS+) prior to review at the clinic.
We identified 119 children with a VPS as their first seizure, of which 61 (51%) went on to have other seizures (VPS+). Children with VPS+ were more likely to present at a younger age (6.2 vs 12.5 months, P = 0.03), with afebrile seizures (42.6% vs 15.5%, P = 0.002) compared to VPS only children. VPS recurrence on revaccination was uncommon in both groups, but more common in VPS+ children (12.5% vs 2.4%, P = 0.07). Having an epilepsy diagnosis, specifically Dravet syndrome, was associated with VPS recurrence (P < 0.001). Of the four children with Dravet syndrome who had VPS recurrence, all had status epilepticus following revaccination.
In children who presented with a single VPS as their only seizure, VPS recurrence on revaccination was uncommon. Children who had multiple non-vaccine proximate seizures following their initial VPS (VPS+) were more likely to present with afebrile VPS, at a younger age and have a VPS recurrence with vaccination. In these children, particularly those aged < 12 months, assessment and investigation for diagnosis of Dravet syndrome should be considered and additional precautions for revaccination undertaken as they are at highest risk of VPS recurrence.
在接种疫苗后 14 天内发生的发热或不发热的癫痫发作可被视为疫苗相关癫痫发作 (VPS)。虽然首次发热性 VPS 的归因风险和临床严重程度已得到充分认识,但 VPS 复发的风险和临床结局则不太明确。
我们对 2013 年至 2017 年期间在澳大利亚专科免疫接种诊所因 VPS 而首次发作的儿童进行了回顾性再接种管理和结局研究。将 VPS 仅为首次发作(VPS 仅)的儿童与 VPS 后首次就诊前发生其他非疫苗相关癫痫发作(VPS+)的儿童的疫苗接种结果进行了比较。
我们共发现 119 例因 VPS 而首次发作的儿童,其中 61 例(51%)出现了其他发作(VPS+)。VPS+儿童更有可能在较小年龄(6.2 个月与 12.5 个月,P=0.03),且无热惊厥(42.6%与 15.5%,P=0.002)的情况下就诊。两组 VPS 复发在再接种时均不常见,但 VPS+儿童更常见(12.5%与 2.4%,P=0.07)。患有癫痫诊断,特别是德雷韦综合征,与 VPS 复发相关(P<0.001)。在 4 例有 VPS 复发的德雷韦综合征儿童中,所有儿童在再接种后均发生癫痫持续状态。
在仅出现一次 VPS 作为唯一发作的儿童中,再接种时 VPS 复发并不常见。在首次 VPS 后发生多次非疫苗相关癫痫发作(VPS+)的儿童中,更有可能出现无热 VPS,且年龄更小,并在接种疫苗时发生 VPS 复发。对于这些儿童,特别是年龄<12 个月的儿童,应考虑诊断德雷韦综合征的评估和调查,并应采取额外的预防接种措施,因为他们的 VPS 复发风险最高。